Search Results - "JELINKOVA, I"
-
1
5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53
Published in Oncotarget (22-12-2015)“…Despite recent advances in targeted therapeutics, administration of 5-fluorouracil (5-FU) remains a common clinical strategy for post-surgical treatment of…”
Get full text
Journal Article -
2
The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis
Published in Journal of clinical virology (01-02-2000)“…Background: The biological properties of some herpesviruses such as the ability of latent persistency in the host cells and the presence of viral DNA in…”
Get full text
Journal Article -
3
-
4
Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells
Published in Cell proliferation (01-12-2013)“…Objectives Therapeutic potential of conventionally used platinum‐based drugs in treatment of colorectal tumours has been limited due to high incidence of…”
Get full text
Journal Article -
5
Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway
Published in Carcinogenesis (New York) (2011)“…TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) can selectively trigger apoptosis in various cancer cell types. However, many cancer cells are…”
Get full text
Journal Article -
6
Correction: 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53
Published in Oncotarget (10-05-2016)Get full text
Journal Article -
7
A518 Dendritic Cells Immunotherapy: A Phase II Clinical Trial
Published in Clinical lymphoma & myeloma (01-02-2009)Get full text
Journal Article -
8
The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells
Published in Klinická onkologie (2009)“…On June 2006, phase II clinical trial focused on anticancer vaccination of multiple myeloma patients, was started. On September 2007, the immune and clinical…”
Get more information
Journal Article